Vaximm AG's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be adapted to target a wide range of cancer-related antigens. Vaximm's most advanced compound, VXM01, is in Phase I/IIa studies with data expected in early 2017.
Dr. Matthias Schroff was appointed CEO of Vaximm in September this year; previously he was CEO of Mologen AG,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?